SuperGen to Present at BioEquity Europe on May 23rd & 24th

DUBLIN, Calif.--(BUSINESS WIRE)-- SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., president and chief executive officer, will present at BioEquity Europe 2011 on Monday and Tuesday, May 23rd and 24th in Paris.

SuperGen's corporate presentation will take place on May 23 at 11:00 a.m. CEST. In addition, Dr. Manuso will participate in a panel discussion titled, “Strategy: Squaring the Circle” about building companies to study disease biology based on platform technology, on May 24 at 1:45 p.m. CEST. More information on the panel can be found at http://www.biocentury.com/Conferences.

About SuperGen

SuperGen is a pharmaceutical company dedicated to discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. On April 6, 2011, SuperGen entered into a definitive merger agreement to acquire Astex Therapeutics Limited, a UK based biotechnology company. The transaction is subject to customary regulatory, legal and shareholder approvals. For more information about SuperGen, please visit http://www.supergen.com.



CONTACT:

SuperGen, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Business Dev.
[email protected]
Susanna Chau, 925-560-2845
Manager
Investor Relations
[email protected]
or
The Trout Group
Alan Roemer, 646-378-2945
Senior Vice President
[email protected]
or
Fleishman-Hillard
Michael Ares, 404-739-0133
Senior Vice President
[email protected]

KEYWORDS:   United States  Europe  North America  California  France

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.